CASI Pharmaceuticals - התחייבויות לטווח ארוך של החברה CASI

CASI Pharmaceuticals (CASI) is a reputable intermediary providing access to advanced blood cancer treatments for residents of China. The business relies on strict compliance with NMPA regulations, which creates a significant barrier to entry for new players. The licensing model for Western drugs minimizes R&D risks, and the debt load ratio is 0.00. This chart of current share prices on GURU.Markets confirms the holding's market positions.

To select high-quality assets, investors analyze the liability structure to assess capital resilience against long-term risks. This metric captures the total amount of loans with maturities exceeding one year, reflecting the balance between financial security and expansion rates, which is critical for CASI Pharmaceuticals (CASI) when financing costly clinical trials for oncology drugs and developing its R&D pipeline, based on the company's current level of long-term debt.